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The retinoblastoma protein pRb is essential for regu-
lating many cellular activities through its binding and
inhibition of E2F transcription activators, and pRb
inactivation leads to many cancers. pRb activity
can be perturbed by viral oncoproteins including
human papillomavirus (HPV) that share an LxCxE
motif. Because there are no treatments for existing
HPV infection leading to nearly all cervical cancers
and other cancers to a lesser extent, we screened
for compounds that inhibit the ability of HPV-E7 to
disrupt pRb/E2F complexes. This lead to the iden-
tification of thiadiazolidinedione compounds that
bind to pRb with mid-high nanomolar dissociation
constants, are competitive with the binding of viral
oncoproteins containing an LxCxE motif, and are
selectively cytotoxic in HPV-positive cells alone and
in mice. These inhibitors provide a promising scaf-
fold for the development of therapies to treat HPV-
mediated pathologies.
INTRODUCTION
The retinoblastoma protein (pRb) was the first protein identified
whose mutational inactivation was associated with cancer, a
childhood cancer of the eye (Schubert et al., 1994). pRb is now
known to have altered activity in many other cancers includ-
ing osteosarcomas, lung carcinomas, and bladder carcinomas
(Cordon-Cardo et al., 1997; Hensel et al., 1990; Kitchin and
Ellsworth, 1974). pRb is also a target for inactivation by the viral
oncoproteins E1a, E7, and T-antigen from adenovirus, human
papillomavirus (HPV), and simian virus 40, respectively (Felsani
et al., 2006). The normal function of pRb is to regulate the cell
cycle, apoptosis, and differentiation through its direct binding
to and inhibition of the E2F family of transcription factors
(Harbour and Dean, 2000; Stevaux and Dyson, 2002). When
phosphorylated, pRb releases E2F proteins to transcribe genes
necessary for the progression into the S-phase of the cell cycle,518 Chemistry & Biology 19, 518–528, April 20, 2012 ª2012 Elsevieras well as for DNA replication (Harbour and Dean, 2000; Harbour
et al., 1999; Stevaux and Dyson, 2002). The viral oncoproteins
act by binding to hypophosphorylated pRb, disrupting pRb/
E2F complexes and thereby leading to dysregulated entry into
S-phase of the cell cycle and neoplasia (Ganguly and Parihar,
2009; Mu¨nger et al., 2001). HPV-E7 has also been implicated
in the degradation of pRb (Boyer et al., 1996; Giarre` et al.,
2001; Gonzalez et al., 2001).
Each of the viral oncoproteins that inhibit pRb function employ
a conserved LxCxE sequence for high affinity pRb binding
although they each use other protein regions to contribute to
the disruption of pRb/E2F complexes through distinct mech-
anisms (Felsani et al., 2006; Liu and Marmorstein, 2006). The
A and B cyclin fold domains of pRb form the ‘‘pocket’’ region,
which forms a groove that makes high affinity contacts to
the transactivation domain of E2F (Xiao et al., 2003). The LxCxE
motif from viral oncoproteins contribute to disruption of pRb/E2F
complexes by binding to the pRb B domain (Lee et al., 1998).
Although the A/B pocket of pRb is important for its biological
activity, the C-terminal domain is also important for the formation
of pRb-E2F complexes and is the target of other regions of the
viral oncoproteins. The C-terminal domain of pRb has been
shown to make contacts with the marked-box region of E2F,
although with a lower affinity (Rubin et al., 2005). This domain
of pRb is also subject to cell-cycle dependent posttranslational
modifications, such as phosphorylation and acetylation, as well
as the recruitment of cyclins/cyclin-dependent kinases (Adams
et al., 1999).
Of the viruses that target pRb function, HPV has received
considerable attention due to its role in human cancer. In partic-
ular, HPV is known to be the causative agent of a number of
epithelial cancers, most notably cervical cancer, a leading cause
of death for women worldwide (McLaughlin-Drubin and Mu¨nger,
2009). HPV infection has also been implicated to have a causa-
tive role in 20% of head and neck cancers as well as several
other cancers (Dufour et al., 2012; Sudhoff et al., 2011). There
are over 200 HPV genotypes that have been recognized, and
they fall under two general forms based on the pathology of
the lesions that they cause, low-risk and high-risk, which cause
benign tumors and which have the propensity to cause cancer,
respectively (Burd, 2003). Two prophylactic vaccines areLtd All rights reserved
Table 1. Chemical Libraries Employed and Hits Obtained for HPV-E7 Inhibitor Solution Screen
Library Compounds (n) Cherry Picks (n) Hit Percentage (%) ELISA IC50 <15.6 mM
Spectrum 2,000 11 0.55 3
Maybridge HitFinder 14,400 32 0.22 13
OPS, set 9 7,952 50 0.63 16
OPS, sets 3–6, 10, 12–14 63,587 271 0.43 88
Total 87,939 364 0.41 120
See also Figure S2.
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Small Molecule Antagonists of pRb Inhibitioncurrently available, Gardasil and Cervarix, which help prevent
against infection by the low risk HPV types 6 and 11 and high
risk HPV types 16 and 18 (Harper, 2009). Whereas these
vaccines target HPV types that cause more than 90% of genital
warts and cervical cancer, therapeutic treatments are still
needed for those who have already been exposed to the virus.
Toward the development of HPV therapeutics a group of
related small molecule compounds have been identified through
high throughput screening that can disrupt the HPV E1-E2 inter-
action and prevent viral replication (White et al., 2011; Yoakim
et al., 2003) and optimized to obtain compounds with low nano-
molar IC50 values (Goudreau et al., 2007; Wang et al., 2004).
Several inhibitors that target the HPV-E6 interaction with E6AP
that is required for p53 degradation have also been developed
including the Pitx2a protein inhibitor (Wei, 2005), intra-
bodies(Griffin et al., 2006) and a-helical peptides (Butz et al.,
2000; Liu et al., 2004), however, all show modest activity. Ten
small molecules inhibitors were also identified by Baleja et al.
(2006) after pharmacophore development and limited in silico
screening, however, only one compound proved to be active in
cells and only at high concentrations. Although these studies
have not progressed to clinical trials, it demonstrates that it is
possible to target HPV protein-protein interactions effectively
with small molecules. HPV-E7 is a particularly attractive protein
target because it is one of the cancer-causing oncoproteins
from this virus and it has no human ortholog. To date, there are
no known small molecule inhibitors that target HPV-E7.
Here we describe a high-throughput solution screen of
88,000 compounds resulting in the identification and charac-
terization of a family of small molecule thiadiazolidinedione
compounds that we show inhibit the ability of HPV-E7 to disrupt
pRb/E2F complexes. We also show that these inhibitors bind
directly to pRb with dissociation constants in the mid-high nano-
molar range, are competitive for pRb binding to other viral onco-
proteins containing an LxCxEmotif, and are selectively cytotoxic
to cells transformed with high-risk forms of HPV alone and
in mice. These inhibitors provide tools to probe mechanisms
involved in HPV transformed cells and may provide a promising
chemical scaffold to develop novel therapies to treat HPV-medi-
ated pathologies.
RESULTS
Identification of HPV-E7 Inhibitors Using
a High-Throughput Solution Screen
Approximately 88,000 compounds from several diverse small
molecule libraries (Table 1) were screened to search for inhibitors
that prevent E7-mediated displacement of E2F from pRb. TheChemistry & Biology 19,protein constructs that were employed include: 6xHis-HPV16-
E7CR2-3 (residues 17–98) harboring conserved regions 2 and 3
and the LxCxE motif of HPV-E7 (Figure 1A), GST-pRbABC (resi-
dues 376–928) harboring the A/B pocket domain and C-terminal
region of pRb, and untagged E2FMB-TA (residues 243–437) con-
taining the marked-box and transactivation domains of E2F
that make pRb contact. 6xHis-HPV16-E7CR2-3 was modified to
improve its solubility and reduce its tendency to aggregate
by substituting two nonconserved cysteine residues in its CR3
domain to the corresponding residues found in low-risk
HPV1A-E7 (Figure 1A). This mutated form of E7 was confirmed
to be properly folded according to its elution profile on gel filtra-
tion (data not shown), and it exhibited the ability to bind specifi-
cally to pRb and dissociate pRb/E2F complexes, as expected
(Figure S1 available online). Furthermore, this E7 mutant was ex-
pected to bind pRb with comparable affinity to wild-type E7
because the mutated residues were not located in regions
that were shown to mediate pRb binding. The assay used for
screening employed an ELISA as illustrated in Figure S2A. A
GST-pRbABC/ E2FMB-TA complex was bound to a glutathione-
coated 384-well microtiter plate and incubated with 6xHis-
HPV16-E7CR2-3 in the presence of 1% DMSO (negative control)
or 6.25–12.5 mM of compound dissolved in DMSO. Compounds
that inhibit HPV-E7-mediated disruption of pRb/E2F complexes
maintain E2F bound to the plate through pRb. Therefore,
following plate washing, the amount of E2F remaining bound to
the plate, as quantified by a bioassay, is correlated to the
potency of the compound in inhibiting HPV-E7-mediated disrup-
tion of pRb/E2F complexes.
The initial screen resulted in the identification of 364 small
molecule HPV-E7 inhibitors. Using liquid stock from the libraries
used for screening, we retested the activity and potency of all
364 candidate inhibitors in the primary screening assay. These
retest experiments confirmed activity for 120 of the 364 with
IC50 values of 15.6 mM or lower. The remaining 244 compounds
either did not show reproducible inhibition, or were not suffi-
ciently potent andwere discarded from further analyses (Table 1).
The 120 confirmed actives were then tested in secondary assays
as described below to identify those with selective pharma-
cological activity in cells. A summary of the process for the iden-
tification of confirmed screening hits is shown in Figure S2B.
Additional information for interpreting and repeating the screen
is provided in Table S1.
A Family of Thiadiazolidinedione Compounds Are
Selective for HPV 16-Transformed Cells
To reduce the number of compounds from the primary screen
for further characterization, the 120 confirmed hits with IC50518–528, April 20, 2012 ª2012 Elsevier Ltd All rights reserved 519
Figure 1. Characterization of Small Molecule HPV-E7 Inhibitors
(A) Sequence alignment of E7 from HPV 1A, HPV 16, and HPV 18 used in the experiments. The two residues in red in HPV 16 E7 were mutated to the corre-
sponding residues in HPV 1A E7 for use in the biochemical experiments.
(B) IC50 curves for disruption of pRb/E2F complexes by E7 in the presence of a family of thiadiazolidinedione compounds. IC50 curves were generated using the
ELISA-based assay described in the Experimental Procedures. Ten-fold dilutions of inhibitor, starting at 100 mMwere added to amixture containing GST-pRbABC/
E2FMB-TA and 6xHis-HPV16-E7CR2-3. The amount of E2FMB-TA remaining was determined by adding a primary antibody specific for E2F1.
(C) IC50 curves for inhibitor disruption of HPV-E7/pRb complexes. IC50 curves were generated using the ELISA assay with 10-fold dilutions of inhibitor, starting at
100 mM were added to a mixture containing GST-pRbABC and 6xHis-HPV16E7CR2-3. The amount of E7 remaining was determined by adding a primary anti-His
antibody. The error bars in (B) and (C) were obtained from the standard errors generated by Graphpad using triplicate data.
(D) Effect of inhibitors on HPV-E7/pRb pull-down. Different concentrations of inhibitor (compound 478166 is shown) were added and the amount of GST-E7FL
remaining bound to pRb was probed by using an anti-GST antibody (bottom panel). The top panel shows the loading control of His-pRbABC in each lane.
See also Figure S1.
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their ability to be cytotoxic or to inhibit proliferation of cervical
cancer cells either transformed with HPV16 (SiHa) or not
(C-33A) (Yee et al., 1985). The metabolic viability of cells was
measured using an MTS assay (3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium).
Compounds were tested at a concentration range of 25 mM to520 Chemistry & Biology 19, 518–528, April 20, 2012 ª2012 Elsevier100 nM. Staurosporine, a nonspecific kinase inhibitor, was
used as a positive control because it was expected to be toxic
in all cells (Ru¨egg and Burgess, 1989). The 120 confirmed hits
were incubated with cells for 48 hr prior to the addition of MTS
reagent. The absorbance at 490 nm was determined within
3 hr of incubation with MTS reagent. Out of the 120 compounds
tested, 25 were either selectively cytotoxic or selectivelyLtd All rights reserved
Table 2. IC50 Values for Compounds to Inhibit HPV-E7-Mediated Disruption of pRb/E2F Complexes and for Disrupting pRb/Viral
Oncoprotein Complexes
All values indicated are from experiments that were done in triplicate.
See also Tables S1, S3, and S4.
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C-33A (HPV negative) cells at concentrations at or below 6 mM
(data not shown).
Of the 25 compounds that were selectively cytotoxic or pre-
vented proliferation of SiHa cells, seven shared a similar thiadia-
zolidinedione ring scaffold attached to a phenyl ring with various
substitution patterns attached (Table 2) and had IC50 values in
the ELISA assay that ranged between 0.34–7.6 mM (Figure 1B
and Table 2). The remaining compounds were eliminated from
further studies due to a variety of reasons including poor repro-
ducibility in activity, significant impurities, and/or structural
features suggestive of reactivity, aggregation or other nonspe-
cific mechanisms (Table S2). Consequently, our studies focused
on characterizing the mechanism of inhibition for the seven thia-
diazolidinedione compounds listed in Table 2. The purity and
integrity of these seven compounds, ordered as powders, was
confirmed by LC/MS studies and 1 H NMR of a representative
compound (Table S3).Chemistry & Biology 19,Some structure-activity relationship (SAR) information can
be extracted for the seven thiadiazolidinedione compounds. In
most of the compounds, there is a phenyl group with various
substituents attached at the G2 position (Table 2). Interestingly,
compound 478419 has a phenyl group at the G1 position instead
of G2. Given that the compounds are pseudo symmetric, it is
possible that the phenyl group at the G1 position of compound
478419 may compensate for the phenyl group at the G2 position
of the other compounds. This suggests that theremay be at least
two orientations for the thiadiazolidinedione compounds that
allow the phenyl ring to occupy the same binding pocket of its
protein target and inhibit HPV-E7. A number of other structural
analogs were also tested for inhibition in the ELISA assay
(Table S4). These analogs had the sulfur in the heterocycle ring
changed to either a carbon, or oxygen, and showed no activity
(Table 2). This data suggests that the S heterocycle is necessary
for activity, possibly because the larger sulfur atom distorts the
ring in such a way to facilitate hydrogen bonding by the oxygen518–528, April 20, 2012 ª2012 Elsevier Ltd All rights reserved 521
Figure 2. In Vitro Characterization of Thiadiazolidinedione Inhibitors
Against Viral Oncoproteins
(A) Ability of inhibitors to prevent LxCxE containing viral oncoproteins from
disrupting E2F/pRb complexes. Ten-fold dilutions of inhibitor (compound
478166 is shown) were added to GST-pRbABC/6xHis-HPV1AE7CR2-3 or GST-
pRbABC/6xHis-Ad5E1ACR2-3.
(B) Ability of inhibitors to disrupt complexes between pRb and LxCxE
containing viral oncoproteins. Compound 478166 was used for the experiment
shown.
(C) Binding of inhibitors to pRb asmeasured by isothermal titration calorimetry.
The curve fit for pRb binding to compound 478081 reveals 1:1 binding with a
KD of 165 nM, and dH of 1,237 cal/mol.
(D) HPV-E7 binding to pRb in the presence of increasing concentrations of
inhibitor. The ELISA-based assay was used to determine the mechanism of
binding of the small molecules to pRb. Five-fold dilutions of inhibitor were
added to pRb and the amount of E7 that was able to bind to pRb was deter-
mined. The calculated apparent KD values for pRB-E7 in the presence of 0.025,
0.25, 0.5, and 5.0 mMof inhibitor 478165 (KD for pRb of 104 nM) were 140 ± 22,
313 ± 21, 304 ± 76, and 764 ± 72 nM, respectively. The error bars in (A), (B), and
(D) were obtained from the standard errors generated by Graphpad using
triplicate data.
See also Figure S3.
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that supports activity that the C or O analogs do not.
The HPV-E7 Inhibitors Function to Disrupt HPV-E7
Interaction with pRb
Because HPV-E7 interacts with both pRb and E2F for disruption
of the pRb/E2F complex, we sought to confirm that the seven
active compounds inhibited HPV-E7 activity by directly disrupt-
ing HPV-E7 interactions with pRb (Liu et al., 2006; Mu¨nger et al.,
2001). For these experiments, we modified the ELISA assay to
measure the amount of 6xHis-HPV16-E7CR2-3 remaining bound
to pRb. We found that an increase in compound concentra-
tion led to a displacement of 6xHis-HPV16-E7CR2-3 from GST-
pRbABC, suggesting that the compounds prevent the interaction
between these two proteins (Figure 1C). To eliminate potential
artifacts from this assay format, we tested the ability of the
HPV-E7 inhibitors to disrupt HPV-E7/pRb interaction by per-522 Chemistry & Biology 19, 518–528, April 20, 2012 ª2012 Elsevierforming pull-downs on Ni-NTA beads using His-pRbABC and
GST-tagged full length 16E7 (GST-16E7FL) (Figure 1D). Consis-
tent with the ELISA assay, the pull-down assay shows that an
increase in compound concentration leads to a displacement
of GST-E7FL from His-pRbABC. The IC50 values for the amount
of respective compound required for 6xHis-HPV16-E7CR2-3
displacement from GST-pRbABC, as determined by the ELISA
assay, were within 10-fold of the corresponding IC50 values of
E2F displacement from GST-pRbABC in the presence of 6xHis-
HPV16-E7CR2-3 (Table 2). These data are consistent with the
observation that preventing HPV-E7 binding to pRb inhibits its
ability to displace E2F from pRb (Liu et al., 2006; Mu¨nger et al.,
2001).
The HPV-E7 Inhibitors Function by Binding to pRb
through the LxCxE Binding Motif of Viral Oncoproteins
Because HPV-E7 mediates high affinity pRb binding through the
association of its LxCxE motif in its CR2 domain to the B domain
of pRb, we hypothesized that the HPV-E7 inhibitors might bind
to either the LxCxE motif of HPV-E7 or the B-domain of pRb.
To distinguish between these possibilities, we assayed the ability
of the thiadiazolidinedione compounds to inhibit the ability
of other LxCxE containing viral oncoproteins from disrupting
E2F/pRb complexes: HPV-E7 from a low risk HPV form (type 1A)
and Adenovirus E1A proteins. E1A was used as a control
because it does not dimerize in solution, unlike E7, and has
also been shown to displace E2F via a different mechanism
(Felsani et al., 2006). For these studies, we modified our ELISA
assay to measure disruption of E2F/pRb complexes by sub-
stituting 6xHis-HPV1AE7CR2-3 and 6xHis-Ad5E1ACR1-3. As
illustrated in Figure 2A and Table 2, the thiadiazolidinedione
compounds show similar levels of inhibition as they did in the
presence of 6xHis-HPV16E7CR2-3. The ability of the compounds
to prevent an interaction between either 6xHis-HPV1AE7CR2-3 or
6xHis-Ad5E1ACR1-3 with GST-pRbABC was also demonstrated
(Figure 2B). The IC50 values from these experiments ranged
from 0.2–11.2 mM, comparable to the IC50 values for com-
pound inhibition of HPV-16E7 mediated inhibition of E2F/pRb
complexes (Table 2). These data suggest that the thiadiazolidi-
nedione inhibitors disrupt the interaction between the pRb B
domain and the LxCxE motif of the viral oncoproteins.
Because the LxCxEmotif from the viral oncoproteins is likely to
be extended and flexible when not in complex with partner
proteins, we postulated that the small molecule thiadiazolidine-
dione inhibitors interact with the structured pRb B domain (Lee
et al., 1998). To test this hypothesis, we assayed the ability of
the HPV-E7 inhibitors to bind directly to a truncated pRb protein
construct containing the A and B domains of the pRb pocket
(pRbAB) using isothermal titration calorimetry (ITC). The resulting
integrated heat-flow spikes confirmed direct binding of inhibitors
to pRb with 1:1 stoichiometry and affinities in the submicromolar
range (Figures 2C and S3A). The dissociation constants obtained
range from100–800 nMandare provided in Table 2. The reported
KD for the LxCxEE7peptide binding topRb is110nM (Leeet al.,
1998) and is comparable to the KD values obtained for pRb
binding to the inhibitors. Toconfirm that inhibitorbinding is revers-
ible, one of the pRb/inhibitor complexes (pRb with compound
478166)wasdialyzedovernight and ITCwas repeated. As before,
a binding curve was obtained yielding a similar dissociationLtd All rights reserved
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still able to interact with pRb in a reversible fashion (Figure S3B).
Toeliminate thepossibility of nonspecificbindingof the thiadiazo-
lidinediones, ITC was carried out with compound 478166 and
6xHis-HPV16-E7CR2-3 (Figure S3C). The observed heats reveals
negligible binding, further demonstrating that the compounds
are not binding to pRb nonspecifically.
To determine if the inhibitors are competitive with HPV-E7 for
pRb binding or work through an allosteric mechanism, we em-
ployed the ELISA assay to measure the ability of HPV-E7 to
displace the compound from pRb as a function of inhibitor
concentration. As shown in Figure 2D, the binding curves of
6xHis-HPV16-E7CR2-3 to GST-pRbABC in the presence of varying
concentrations of inhibitor, above and below the dissociation
constant of pRb for inhibitor, shows a dependence on the con-
centration of inhibitor used, where increasing inhibitor concen-
tration is correlated with a rightward shift (higher apparent value)
in the Kd values for HPV-E7 binding to pRb. This data suggests
that inhibitor and HPV16-E7 bind competitively to pRb. Taking
this result together with the observation that these inhibitors
are also able to disrupt pRb complexes with HPV1A-E7 and
Ad5-E1a (Figure 2A) suggests that these thiadiazolidinedione
inhibitors also bind pRb competitively with other LxCxE contain-
ing oncoproteins.
HPV-E7 Inhibitors Selectively Cause Apoptosis
in HPV-Transformed Cells
Because the seven thiadiazolidinediones listed in Table 2 were
cytotoxic or prevented proliferation of SiHa cells due to their
role in inactivating pRb, which is mutated in C-33A cells, they
were tested in additional cell lines: TC-1, a mouse epithelial
line cotransformed with HPV 16 E6/E7 and c-Ha-Ras, HeLa,
a human cell line transformedwith HPV 18 andHCT116, a human
HPV negative colorectal carcinoma cell line containing an intact
retinoblastoma gene (DeFilippis et al., 2003; Scheffner et al.,
1991; Yee et al., 1985). The levels of cell viability after incubation
with compound were determined using the MTS assay as previ-
ously described. This time, a concentration range of 100 mM to
3 mM of compound was tested so that the cellular IC50 values
could be extracted for these seven compounds, and for the
ten inactive analogs. As shown in Figure 3, the thiadiazolidine-
dione compounds had the greatest effect on SiHa cells, followed
by TC-1 cells, and to a smaller extent, HeLa cells. The smallest
effect was seen in HCT 116 and C-33A cells. Although the inhib-
itors were cytotoxic in all cell lines at 100 mM, they were selec-
tively cytotoxic in HPV-positive cells at the lower compound
concentrations. In general, the IC50 values of the thiadiazolidine-
dione compounds in SiHa cells varied frombetween 6.25 mMand
12.5 mM to between 25 mM and 50 mM. The IC50 values in TC-1
and HeLa cells were slightly higher and varied from between
12.5 mM and 25 mM to between 50 mM and 100 mM. The IC50
values in HCT 116 and C-33A cells were all >25 mM. Importantly,
the inactive analogs did not demonstrate any effect in any of the
cell lines tested (a representative example is shown in Figure 3).
Taken together, this data suggests that the seven thiadiazolidi-
nedione HPV-E7 inhibitors identified in the primary HTS are
either selectively cytotoxic or selectively prevent proliferation
of HPV transformed cervical cancer cell lines, with a greater
effect in cell lines transformed with HPV 16.Chemistry & Biology 19,Given that the thiadiazolidinedione inhibitors bind to pRb,
a critical regulator of the cell cycle, we asked whether they
perturb the cell cycle to prevent proliferation or whether they
induce apoptosis in cells transformed with HPV. To carry out
these studies, we employed SiHa cells (transformed with
HPV 16) because the inhibitors were most effective in this cell
line. Cells were treated with either DMSO or 10 mM of two re-
presentative thiadiazolidinediones: compounds 478166 and
478168, an inactive analog (compound 44234), or 2 mM of staur-
osporine, for 48 hr. DNA content was determined by propidium
iodine staining and analysis by flow cytometry. In agreement
with our biochemical results and the MTS cell viability assay,
compounds 478166, 478168, and staurosporinemost drastically
affected SiHa cells whereas the inactive analog had no effect
(Figures 4 and S4). The thiadiazolidinedione inhibitors caused
an increase of apoptotic SiHa cells (6.5% and 15.2% of cells
were apoptotic when treated with the thiadiazolidinediones
478166 and 478168, respectively, compared to 1% apoptotic
cells that were treated with DMSO or the inactive analog) as
did the nonspecific kinase inhibitor staurosporine (34.3% of cells
were apoptotic) (Figure 4). These results are consistent with the
MTS data and in vitro data, together supporting the interpreta-
tion that the thiadiazolidinedione inhibitors antagonize the ability
of HPV-E7 to maintain the viability of the HPV transformed cells.
These results are also consistent with work by others that E7
knockdown can lead to apoptosis in HPV-positive cells (Jiang
and Milner, 2002; Sima et al., 2008).
A Representative Compound Can Reduce Tumor Size
In Vivo
Because the thiadiazolidinedione inhibitors exhibited apoptotic
activity in cells, we wanted to determine whether or not they
would demonstrate anti-tumor activity in vivo. A transplantable
tumor model was employed in which TC-1 cells were injected
subcutaneously into NOD-SCID mice. After 5 days, treatment
was initiated with compound 478166 (n = 6) or vehicle only
(DMSO) (n = 6) by intraperitoneal injection and repeated daily
for a total of 14 days. The tumors were measured once every
2 days. At the conclusion of treatment, a significant reduction
in tumor volumes was observed for mice treated with compound
compared to vehicle only (Figure 5). After 14 days, the average
tumor volume of mice treated with DMSO was 3,950 mm3,
whereas the average tumor volume of mice treated with drug
was 2,270 mm3 (p < 0.02). Taken together with our results from
the cell-based experiments, it appears that the thiadiazolidine-
dione inhibitor can reduce tumor volume in vivo, with no delete-
rious effects observed otherwise on animal health.
DISCUSSION
We have described the identification and characterization of
structurally similar thiadiazolidinedione compounds that inhibit
the interaction between the LxCxE motif of viral oncoproteins
and pRb in a competitive manner with submicromolar dis-
sociation constants. The identification of these inhibitors is an
important finding given that there are no known inhibitors that
specifically block the interaction of pRb with viral oncopro-
teins. Interestingly, other small molecule compounds that show
structural similarity to these thiadiazolidinediones have been518–528, April 20, 2012 ª2012 Elsevier Ltd All rights reserved 523
Figure 3. Cellular Toxicity of Thiadiazolidinedione Compounds
Four different cervical cancer cells lines: SiHa, TC-1, HeLa, and C-33A and one noncervical cancer cell line, HCT116, were employed for these studies. Two-fold
compound dilutions starting at 100 mMdown to 3.125 mM for the thiadiazolidinediones and starting at 2 mM to 4 nM for staurosporine were incubated for 48 hr with
cells before the addition of MTS reagent. After 1–2 hr of incubation with reagent, the absorbance at 490 nmwas determined. The percent growth was determined
by dividing by the growth in the presence of DMSO control. The error bars represent the SD of the replicate data sets as calculated using Excel.
See also Table S2.
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Figure 4. Effects on the Cell Cycle and Apoptosis by the
Thiadiazolidinediones 478166 and 478168, an Inactive Analog, and
Staurosporine
To determine any effect on cell cycle or apoptosis, SiHa cells were treated with
DMSO or 10 mM of compounds 478166, 478168, 44234 (inactive analog), or
2 mM staurosporine for 48 hr. After 48 hr, cells were harvested, stained with
propidium iodide, and DNA content was analyzed by flow cytometry. The
percent of cells in G0/G1, G2/M, S, or apoptotic were determined by the areas
under the curves represented by (B), (C), (D), and (E), respectively.
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disorders by targeting glycogen synthase kinase-3 (GSK-3)
or the peroxisome proliferator-activated receptor g (PPARg)
(Luna-Medina et al., 2005, 2007; Martinex, 2006; Martinez
et al., 2005, 2002; Rosa et al., 2008). The fact that these inhibitors
appear to prevent oncoproteins from binding to the LxCxE
binding site on pRb suggests that these types of inhibitors
provide another route for therapeutics not only against cervical
cancer, but also for other diseases caused by viral oncoproteins
containing the LxCxE motif.
The B domain of the pRb pocket domain harboring the LxCxE
binding site is also the site of interaction with cellular proteins,
such as histone deacetylases, cyclin D1, chromatin remodeling
enzyme BRG1, and other proteins (Dahiya et al., 2000; RosaChemistry & Biology 19,et al., 2008; Singh et al., 2005). However, our studies in cells
and in mice show that these inhibitors are not overtly cytotoxic
in HPV-negative cells, suggesting that the HPV-E7 inhibitors
do not perturb these endogenous interactions, at least to the
same extent. The tumors formed by TC-1 cells in mice showed
a significant reduction in volume when treated with thiadiazolidi-
nedione 478166, without any noticeable effects on their normal
cells, as indicated by a lack of change in animal behavior,
implying a potential therapeutic for HPV16-related neoplasms.
Furthermore, the cell-based studies reveal that the HPV-E7
inhibitors are more toxic in SiHa cells than HeLa cells. Taken
together with our in vitro data showing that the compounds
bind competitively with E7 to pRb, this suggests that the com-
pounds are either more effective at disrupting the interac-
tion between pRb and HPV16 E7 than pRb and HPV18 E7 or
that the levels of E7 and or pRb are different enough in these
cell lines to result in different toxicities. It is also possible that
HeLa cell viability is not completely dependent on the HPV-E7
oncoprotein due to additional genetic and epigenetic changes
in the tumor genome. Others have shown that the levels of pRb
do in fact differ across cervical cancer cell lines, and that there
is a difference in the level of pRb phosphorylation, with a greater
level of hypophosphorylated pRb in SiHa cells (Scheffner et al.,
1991). This observation is consistent with the level of toxicity
that we observe in the MTS assay and by cell-cycle analysis,
which suggests that the thiadiazolidinedione inhibitors may
bind more avidly to hypophosphorylated pRb to prevent the
interaction with E7. Furthermore, the increase in apoptosis in
SiHa cells upon treatment with the thiadiazolidinedione inhibitors
suggests that the inhibitors are antagonizing the ability of E7 to
maintain the viability of the HPV-positive cell lines.
Although there are reports that E7 has the ability to degrade
pRb (Boyer et al., 1996; Giarre` et al., 2001; Gonzalez et al.,
2001), there are other reports that siRNA or shRNA against E7
results in a dephosphorylation of pRb, and not an increase in
overall pRb levels (Jiang and Milner, 2002; Sima et al., 2008).
The dephosphorylation of pRb by E7 was demonstrated in
SiHa and CaSki cells, both of which are transformed with HPV
16. It is possible that the effect on pRb is cell-line dependent,
as the former studies (Boyer et al., 1996; Giarre` et al., 2001;
Gonzalez et al., 2001) were done using different cell lines.Figure 5. TheAntitumor Effect of Thiadiazo-
lidinedione Compound 478166 In Vivo
A tumor model was constructed by inoculating
2.0 3 105 TC-1 cells into the right flank of 12 NOD
SCID female mice. Treatment was started 5 days
postinjection; themice were treated once a day for
14 days, with intraperitoneal injections of DMSOor
compound 478166 at doses of 10 mg/kg. Tumor
sizes were measured every 2 days. The error bars
represent the SD of the replicate data sets as
calculated using Excel.
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Small Molecule Antagonists of pRb InhibitionWe probed for pRb in SiHa, HeLa, TC-1, and HCT 116 cells that
were incubated for 48 hr with concentrations of compound
478166 as high as 25 mMand did not see any change in the levels
of pRb or in its phosphorylation state (data not shown). pRb was
also probed in the mouse tumors that were treated with com-
pound versus those that were not, and again no change in pRb
levels or in its phosphorylation state could be observed (data
not shown). It is possible that these compounds work differently
from the siRNA and shRNA experiments in that they do not cause
a detectable change in the levels of pRb or its phosphorylation
state in these cell lines.
Our results from ITC confirm that the thiadiazolidinedione
inhibitors bind directly to pRb with submicromolar affinity pro-
viding a route for structure-based-drug design of more potent
and selective HPV inhibitors. The crystal structure of the pocket
domain of pRb has been determined and may prove useful
for cocrystallization of these small molecules with pRbAB
(Balog et al., 2011). Cocrystallization studies of these small
molecules with pRbAB may provide further insight to their
mode of interaction and guide further optimization. Because
HPV mediates cell transformation through the action of two
viral oncoproteins, E6 and E7, where E6 targets the p53 tumor
suppressor for degradation, it might be particularly advan-
tageous to combine these thiadiazolidinedione inhibitors with
inhibitors that prevent E6-mediated p53 degradation to
develop a particularly effective therapeutic strategy to treat
HPV-mediated pathologies.
SIGNIFICANCE
The retinoblastoma protein, pRb, is an important re-
gulator of cells and can cause neoplastic lesions when inac-
tivated bymutations or by viral oncoproteins. Its inactivation
by viral oncoproteinsmakes it a desirable drug target. In this
study, we have identified a class of small molecule inhibitors
that competitively inhibit the interaction of LxCxE motif
containing viral oncoproteins with pRb. We show, in vitro,
that these thiadiazolidinedione inhibitors bind to pRb and
prevent one of the main transforming abilities of these
oncoproteins: the premature disruption of the inhibitory
pRb/E2F complex. We also employ cell-based and animal
studies to demonstrate that these inhibitors exhibit selec-
tive cytotoxicity in HPV positive cells. Little or no effect
was seen in cancer cells not transformed with HPV. Our
in vitro, cell-based-studies, and in vivo results in mice indi-
cate that these thiadiazolidinedione inhibitors may provide
a therapeutic strategy for cancers caused by viruses such
as HPV.
EXPERIMENTAL PROCEDURES
Expression and Purification of Proteins
The DNA encoding HPV16-E7CR2-3 (residues 17–98), HPV1A-E7CR2-3 (resi-
dues 16–93), and Ad5-E1ACR1-3 (residues 36–189) were cloned into the pRSET
vector, containing an N-terminal 6x-histidine tag. HPV-E7 and Ad5-E1A were
expressed in Escherichia coli BL21(DE3) cells overnight at 25C and 18C,
respectively. Cells were lysed by sonication in a buffer containing 20mM
Tris, 7.5, 500 mM NaCl, 35 mM imidazole, 10 mM Zn(OAc)2, 10 mM BME
and 13 PMSF. The cell lysate was centrifuged at 18,000 RPM and the resulting
supernatant was loaded onto a Ni-NTA column pre-equilibrated with 20 mM526 Chemistry & Biology 19, 518–528, April 20, 2012 ª2012 ElsevierTris, 7.5, 500 mM NaCl, 35 mM imidazole, 10 mM Zn(OAc)2, and 10 mM
BME. The column was washed and the bound protein was eluted using an
imidazole gradient from 35 mM to 250 mM. The proteins were further purified
using size exclusion chromatography on a Superdex 200 analytical column
(GE Healthcare Life Sciences) in a buffer containing 20 mM Tris, 7.5,
150 mM NaCl, and 10 mM BME.
DNA encoding pRbABC (residues 376–928) was cloned into the pFAST-Bac
vector, containing an N-terminal GST tag. Protein was expressed in Sf9 cells
for 48 hr before harvesting. The protein was purified as described by themanu-
facturer (Novagen). The plasmid pGex6P-1-E2F1, encoding the marked-box
and transactivation domain of E2F1 (residues 243–437) with an N-terminal
GST tag, was provided by Dr. Steven Gamblin (MRC, Mill Hill, UK). GST-
E2F1MB-TA was expressed in E. coli BL21(DE3) CodonPlus RIL cells (Novagen)
for 5–6 hr at 30C and purified as described elsewhere (Liu et al., 2006). The
GST tag was removed using PreScission Protease (GE Healthcare Life
Sciences) as described elsewhere to yield an untagged E2F1MB-TA for assay
purposes (Liu et al., 2006).
For pull-down studies, GST-tagged full-length HPV-E7 was cloned into
the pGEX-4T-1 vector, expressed in E. coli BL21(DE3) cells, and purified as
described by the manufacturer (Novagen). 6xHis-pRbABC (residues 376–928)
was cloned into the pRSET vector, expressed and purified as described above
for the 6xHis-tagged proteins, except that Zn(OAc)2 was excluded from the
buffers.
For isothermal titration calorimetry studies, untagged pRbAB (372–787 with
the linker from 590–635 removed) was prepared as described elsewhere
(Xiao et al., 2003).Compound Libraries
Two thousand compounds comprising the Spectrum Collection from
MicroSource Discovery Systems (Gaylordsville, CT) were tested at a final
concentration of 8.3 mM. A library of 14,400 chemically diverse compounds
from Maybridge HitFinder (Cambridge, UK) were tested at a final concen-
tration of 12.5 mM. A third set of compounds, comprising 71,539 small mole-
cules, from the orthogonally pooled screening (OPS) libraries, provided by
the Lankenau Chemical Genomics Center (Wynnewood, PA) were tested at
a final concentration 6.25 mM to 12.5 mM. The HitFinder and OPS libraries
were orthogonally compressed to contain 5 or 10 compounds per well,
respectively.ELISA Assays
IC50 values for inhibition of E2F displacement from pRb by E7 + inhibitors were
measured using the same ELISA-based assay as described for the high-
throughput screen (Supplemental Experimental Procedures), except that the
assay was performed manually in 96-well format with all volumes doubled.
All compounds were solubilized to 50 mM in DMSO and diluted for use
in the ELISA-based assay at a final DMSO concentration of <5%. The concen-
trations of the compounds in the IC50 experiment spanned the range of
enzyme activity from no inhibition to complete inhibition. To test E1A-pRb
and E7-pRb binding, the assay was modified so that GST-pRbABC alone
was added to HPV-E7CR2-3 + compound/DMSO, or Ad5-E1ACR1-3 +
compound/DMSO. Mouse monoclonal anti-His antibody (Fisher) (1:10,000)
and mouse monoclonal Ad5-E1A antibody (Abcam) (1:10,000) were used to
detect how much His-E7CR2-3 and E1ACR1-3 remained bound to GST-pRbABC
on the plate, respectively. All other steps remained unchanged. To test the
mode of inhibition by the inhibitors, each compound was first incubated with
pRb for 30–60 min. Different concentrations of HPV- E7CR2-3, ranging from
50 mM down to 0.05 mMwere added to the GST-pRbABC + compound mixture
and allowed to incubate for 30–60 min. The reaction mixture was then
transferred to a glutathione-coated plate, and shaken for 15–20 min. Mouse
monoclonal anti-His antibody (Fisher) (1:10,000) was used to detect how
much HPV-E7CR2-3 remained bound to GST-pRbABC on the plate. Three inde-
pendent IC50 measurements were performed for each compound and the
average and SD values are reported. All data was imported into the GraphPad
Software (Prism) for IC50 or KD determination. To calculate the IC50 or KD
values, the dose-response curves were fit to one-site (Hill slope = 1)
sigmoidal-dose-response curves. The error bars were obtained from the stan-
dard errors generated by the GraphPad software.Ltd All rights reserved
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His-tagged protein pRbABC (10 mg) was incubated with 10 ml Ni-NTA beads
(Fisher) in a buffer containing 20mMTris, 7.5, 150mMNaCl, 35 mM Imidazole,
and 0.05% Tween20 for 15 min. Then, inhibitor and an equimolar amount of
GST-HPV16-E7FL to pRb were added and allowed to incubate at 4
C for
1 hr with gentle agitation. The beads were then washed three times with
1 ml buffer (20 mM Tris, 7.5, 150 mM NaCl, 35 mM Imidazole, and 0.05%
Tween20) and subjected to SDS-page analysis. The samples were transferred
to PVDF membrane to be visualized by western blotting. Anti-GST mouse
monoclonal antibodies (1:2,000) (Calbiochem) and anti-Hismousemonoclonal
antibodies (1:5,000) (Fisher) were used. Bands were visualized by chemilumi-
nescence (Pierce) and exposure to film (Kodak).
Isothermal Titration Calorimetry
ITC was done using a MicroCal VP-ITC isothermal titration calori-
meter (MicroCal). Proteins were dialyzed against a buffer containing 20 mM
HEPES, 7.5, 150 mM sodium chloride, and 0.1 mM Tris carboxy ethyl
phosphene prior to analysis. A total of 8–12 ml injections of 750–1,500 mM
compound (final DMSO concentration of 1.5%) were titrated into 50–150 mM
pRbAB (containing the same percentage of DMSO) pre-equilibrated to
22C. After subtraction of dilution heats, calorimetric data were analyzed
with the MicroCal ORIGIN V5.0 (MicroCal Software, Northampton, MA). Error
values obtained from the MicroCal ORIGIN V5.0 software were averaged and
reported.
Cell Culture
C-33A and SiHa cell lineswere purchased fromATCCand grown in 13minimal
Eagle’s media (MEM, Cellgro) supplemented with 10% fetal bovine serum
(Hyclone), 10 ug/ml penicillin-streptomycin (Cellgro), 2 mM L-glutamine
(Cellgro), 1 mM sodium pyruvate (Cellgro), and 100 uM nonessential amino
acids (GIBCO). HeLa and HCT116 cell lines were generous gifts from the labo-
ratories of Susan Janicki, and Meenhard Herlyn, respectively, and maintained
in the same way.
MTS Cell Proliferation Assay
Cultured cell lines were seeded in 384-well, clear, tissue culture plates (NUNC)
at 10,000, 1,000, 1,000, 1,000, and 2,000 cells/well for C-33A, SiHa, HeLa,
TC-1, or HCT116 cells, respectively. The next day, compound dissolved in
a final DMSO concentration of 0.5% was added to each well and incubated
for 48 hr. Cell viability was then monitored by addition of 8 ml of MTS reagent
(Promega) and measurement at A490 using an Envision multilabel plate reader
within 3 hr of MTS addition.
Flow Cytometry
Cultured cell lines were seeded in 60 mm tissue culture dishes (Falcon) at 1 3
105 cells/well. The next day, 10 mMcompound or DMSOwere added and incu-
bated for 48 hr. Cells were then trypsinized, washed with 1.0 ml PBS, and fixed
in 80%ethanol. Fixed cells were spun at 500 g for 5min, andwashedwith PBS.
Cells were stained with 250 ml propidium iodide (PI), which was prepared by
adding 100 ml 2 mg/ml PI (Sigma) and 10 mg RNase A (Sigma) into 10 ml
PBS. Cells were then analyzed at the Wistar Institute Flow Cytometry Core
Facility.
Mouse Studies
A tumor model was constructed by inoculating 2.0 3 105 TC-1 cells into the
right flank of 12 NOD SCID female mice (Jackson Laboratory, Bar Harbor,
ME). Treatment was started 5 days postinjection, as tumors became
palpable. The mice were treated once a day for 14 days, with intraperitoneal
injections of DMSO (0.1%) or compound 478166 at doses of 10 mg/kg.
Tumor sizes were measured every 2 days with calipers and tumor volume,
V, (in mm3) was calculated using ‘‘V = l 3 w2 3 p/6.’’ At the end of the exper-
iment, all mice were sacrificed and the weights of the detached tumors were
measured. The experiments were performed twice with similar results. Statis-
tical analysis was done using the paired Student’s t test. Errors were obtained
by calculating the SDs from all the mice in each set. All animal experiments
were approved by the Wistar Institutional Animal Care and Use Committee
and performed in accordance with relevant institutional and national
guidelines.Chemistry & Biology 19,SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, four tables, and Supple-
mental Experimental Procedures and can be found with this article online at
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ACKNOWLEDGMENTS
This work was supported by NIH grant CA094165 and a Hiliary Koprowski,
M.D. Professorship awarded to R.M. and NIH grant R43EB009626 awarded
toM.R. D.F was supported by NIH training grant GM071339.We acknowledge
support of the Protein Expression and Libraries and Flow Cytometry core
facilities at the Wistar Institute. The Protein Expression and Libraries core
facility at theWistar Institute was supported by NIH grant CA010815.We thank
Jason Bodily and Laimonis Laimins (Northwestern University) for helpful
discussions.
Received: October 12, 2011
Revised: January 21, 2012
Accepted: March 1, 2012
Published: April 19, 2012
REFERENCES
Adams, P.D., Li, X.T., Sellers, W.R., Baker, K.B., Leng, X.H., Harper, J.W.,
Taya, Y., and Kaelin, W.G., Jr. (1999). Retinoblastoma protein contains
a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexes.
Mol. Cell. Biol. 19, 1068–1080.
Baleja, J.D., Cherry, J.J., Liu, Z., Gao, H., Nicklaus, M.C., Voigt, J.H., Chen,
J.J., and Androphy, E.J. (2006). Identification of inhibitors to papillomavirus
type 16 E6 protein based on three-dimensional structures of interacting
proteins. Antiviral Res. 72, 49–59.
Balog, E.R., Burke, J.R., Hura, G.L., and Rubin, S.M. (2011). Crystal structure
of the unliganded retinoblastoma protein pocket domain. Proteins 79, 2010–
2014.
Boyer, S.N., Wazer, D.E., and Band, V. (1996). E7 protein of human papilloma
virus-16 induces degradation of retinoblastoma protein through the ubiquitin-
proteasome pathway. Cancer Res. 56, 4620–4624.
Burd, E.M. (2003). Human papillomavirus and cervical cancer. Clin. Microbiol.
Rev. 16, 1–17.
Butz, K., Denk, C., Ullmann, A., Scheffner, M., and Hoppe-Seyler, F. (2000).
Induction of apoptosis in human papillomaviruspositive cancer cells by
peptide aptamers targeting the viral E6 oncoprotein. Proc. Natl. Acad. Sci.
USA 97, 6693–6697.
Cordon-Cardo, C., Sheinfeld, J., and Dalbagni, G. (1997). Genetic studies and
molecular markers of bladder cancer. Semin. Surg. Oncol. 13, 319–327.
Dahiya, A., Gavin, M.R., Luo, R.X., and Dean, D.C. (2000). Role of the LXCXE
binding site in Rb function. Mol. Cell. Biol. 20, 6799–6805.
DeFilippis, R.A., Goodwin, E.C., Wu, L., and DiMaio, D. (2003). Endogenous
human papillomavirus E6 and E7 proteins differentially regulate proliferation,
senescence, and apoptosis in HeLa cervical carcinoma cells. J. Virol. 77,
1551–1563.
Dufour, X., Beby-Defaux, A., Agius, G., and Lacau St. Guily, J. (2012). HPV
and head and neck cancer. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 129,
26–31.
Felsani, A., Mileo, A.M., and Paggi, M.G. (2006). Retinoblastoma family
proteins as key targets of the small DNA virus oncoproteins. Oncogene 25,
5277–5285.
Ganguly, N., and Parihar, S.P. (2009). Human papillomavirus E6 and E7 onco-
proteins as risk factors for tumorigenesis. J. Biosci. 34, 113–123.
Giarre`, M., Caldeira, S., Malanchi, I., Ciccolini, F., Lea˜o, M.J., and Tommasino,
M. (2001). Induction of pRb degradation by the human papillomavirus type 16
E7 protein is essential to efficiently overcome p16INK4a-imposedG1 cell cycle
Arrest. J. Virol. 75, 4705–4712.518–528, April 20, 2012 ª2012 Elsevier Ltd All rights reserved 527
Chemistry & Biology
Small Molecule Antagonists of pRb InhibitionGonzalez, S.L., Stremlau, M., He, X., Basile, J.R., and Mu¨nger, K. (2001).
Degradation of the retinoblastoma tumor suppressor by the human papil-
lomavirus type 16 E7 oncoprotein is important for functional inactiva-
tion and is separable from proteasomal degradation of E7. J. Virol. 75,
7583–7591.
Goudreau, N., Cameron, D.R., De´ziel, R., Hache´, B., Jakalian, A., Malenfant,
E., Naud, J., Ogilvie, W.W., O’Meara, J., White, P.W., and Yoakim, C. (2007).
Optimization and determination of the absolute configuration of a series of
potent inhibitors of human papillomavirus type-11 E1-E2 protein-protein inter-
action: a combined medicinal chemistry, NMR and computational chemistry
approach. Bioorg. Med. Chem. 15, 2690–2700.
Griffin, H., Elston, R., Jackson, D., Ansell, K., Coleman, M., Winter, G., and
Doorbar, J. (2006). Inhibition of papillomavirus protein function in cervical
cancer cells by intrabody targeting. J. Mol. Biol. 355, 360–378.
Harbour, J.W., and Dean, D.C. (2000). The Rb/E2F pathway: expanding roles
and emerging paradigms. Genes Dev. 14, 2393–2409.
Harbour, J.W., Luo, R.X., Dei Santi, A., Postigo, A.A., and Dean, D.C. (1999).
Cdk phosphorylation triggers sequential intramolecular interactions that
progressively block Rb functions as cells move through G1. Cell 98, 859–869.
Harper, D.M. (2009). Currently approved prophylactic HPV vaccines. Expert
Rev. Vaccines 8, 1663–1679.
Hensel, C.H., Hsieh, C.L., Gazdar, A.F., Johnson, B.E., Sakaguchi, A.Y.,
Naylor, S.L., Lee, W.H., and Lee, E.Y. (1990). Altered structure and expression
of the human retinoblastoma susceptibility gene in small cell lung cancer.
Cancer Res. 50, 3067–3072.
Jiang, M., and Milner, J. (2002). Selective silencing of viral gene expression in
HPV-positive human cervical carcinoma cells treated with siRNA, a primer of
RNA interference. Oncogene 21, 6041–6048.
Kitchin, F.D., and Ellsworth, R.M. (1974). Pleiotropic effects of the gene for reti-
noblastoma. J. Med. Genet. 11, 244–246.
Lee, J.O., Russo, A.A., and Pavletich, N.P. (1998). Structure of the retinoblas-
toma tumour-suppressor pocket domain bound to a peptide from HPV E7.
Nature 391, 859–865.
Liu, X., and Marmorstein, R. (2006). When viral oncoprotein meets tumor
suppressor: a structural view. Genes Dev. 20, 2332–2337.
Liu, X., Clements, A., Zhao, K.H., and Marmorstein, R. (2006). Structure of the
human Papillomavirus E7 oncoprotein and its mechanism for inactivation of
the retinoblastoma tumor suppressor. J. Biol. Chem. 281, 578–586.
Liu, Y., Liu, Z., Androphy, E., Chen, J., and Baleja, J.D. (2004). Design and
characterization of helical peptides that inhibit the E6 protein of papillomavirus.
Biochemistry 43, 7421–7431.
Luna-Medina, R., Cortes-Canteli, M., Alonso, M., Santos, A., Martı´nez, A., and
Perez-Castillo, A. (2005). Regulation of inflammatory response in neural cells
in vitro by thiadiazolidinones derivatives through peroxisome proliferator-acti-
vated receptor gamma activation. J. Biol. Chem. 280, 21453–21462.
Luna-Medina, R., Cortes-Canteli, M., Sanchez-Galiano, S., Morales-Garcia,
J.A., Martinez, A., Santos, A., and Perez-Castillo, A. (2007). NP031112, a thia-
diazolidinone compound, prevents inflammation and neurodegeneration
under excitotoxic conditions: potential therapeutic role in brain disorders.
J. Neurosci. 27, 5766–5776.
Martinex, A. (2006). TDZD: Selective GSK-3 inhibitors with great potential for
Alzheimer disease. Neurobiol. Aging 27, S13–S13.
Martinez, A., Alonso, M., Castro, A., Pe´rez, C., and Moreno, F.J. (2002). First
non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors:
thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer’s
disease. J. Med. Chem. 45, 1292–1299.
Martinez, A., Alonso, M., Castro, A., Dorronsoro, I., Gelpı´, J.L., Luque, F.J.,
Pe´rez, C., and Moreno, F.J. (2005). SAR and 3D-QSAR studies on thiadiazoli-528 Chemistry & Biology 19, 518–528, April 20, 2012 ª2012 Elsevierdinone derivatives: exploration of structural requirements for glycogen syn-
thase kinase 3 inhibitors. J. Med. Chem. 48, 7103–7112.
McLaughlin-Drubin, M.E., and Mu¨nger, K. (2009). Oncogenic activities of
human papillomaviruses. Virus Res. 143, 195–208.
Mu¨nger, K., Basile, J.R., Duensing, S., Eichten, A., Gonzalez, S.L., Grace, M.,
and Zacny, V.L. (2001). Biological activities andmolecular targets of the human
papillomavirus E7 oncoprotein. Oncogene 20, 7888–7898.
Rosa, A.O., Kaster, M.P., Binfare´, R.W., Morales, S., Martı´n-Aparicio, E.,
Navarro-Rico, M.L., Martinez, A., Medina, M., Garcı´a, A.G., Lo´pez, M.G.,
and Rodrigues, A.L. (2008). Antidepressant-like effect of the novel thiadiazoli-
dinone NP031115 in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 32,
1549–1556.
Rubin, S.M., Gall, A.L., Zheng, N., and Pavletich, N.P. (2005). Structure of the
Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-
induced E2F release. Cell 123, 1093–1106.
Ru¨egg, U.T., and Burgess, G.M. (1989). Staurosporine, K-252 and UCN-01:
potent but nonspecific inhibitors of protein kinases. Trends Pharmacol. Sci.
10, 218–220.
Scheffner, M., Mu¨nger, K., Byrne, J.C., and Howley, P.M. (1991). The state of
the p53 and retinoblastoma genes in human cervical carcinoma cell lines.
Proc. Natl. Acad. Sci. USA 88, 5523–5527.
Schubert, E.L., Hansen, M.F., and Strong, L.C. (1994). The retinoblastoma
gene and its significance. Ann. Med. 26, 177–184.
Sima, N., Wang, W., Kong, D., Deng, D., Xu, Q., Zhou, J., Xu, G., Meng, L., Lu,
Y., Wang, S., andMa, D. (2008). RNA interference against HPV16 E7 oncogene
leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via
upregulation of Rb and p53. Apoptosis 13, 273–281.
Singh, M., Krajewski, M., Mikolajka, A., and Holak, T.A. (2005). Molecular
determinants for the complex formation between the retinoblastoma protein
and LXCXE sequences. J. Biol. Chem. 280, 37868–37876.
Stevaux, O., and Dyson, N.J. (2002). A revised picture of the E2F transcrip-
tional network and RB function. Curr. Opin. Cell Biol. 14, 684–691.
Sudhoff, H.H., Schwarze, H.P., Winder, D., Steinstraesser, L., Go¨rner, M.,
Stanley, M., and Goon, P.K. (2011). Evidence for a causal association for
HPV in head and neck cancers. Eur. Arch. Otorhinolaryngol. 268, 1541–1547.
Wang, Y., Coulombe, R., Cameron, D.R., Thauvette, L.,Massariol, M.J., Amon,
L.M., Fink, D., Titolo, S., Welchner, E., Yoakim, C., et al. (2004). Crystal struc-
ture of the E2 transactivation domain of human papillomavirus type 11 bound
to a protein interaction inhibitor. J. Biol. Chem. 279, 6976–6985.
Wei, Q. (2005). Pitx2a binds to human papillomavirus type 18 E6 protein and
inhibits E6-mediated P53 degradation in HeLa cells. J. Biol. Chem. 280,
37790–37797.
White, P.W., Faucher, A.M., and Goudreau, N. (2011). Small molecule inhibi-
tors of the human papillomavirus E1-E2 interaction. Curr. Top. Microbiol.
Immunol. 348, 61–88.
Xiao, B., Spencer, J., Clements, A., Ali-Khan, N., Mittnacht, S., Brocen˜o, C.,
Burghammer, M., Perrakis, A., Marmorstein, R., and Gamblin, S.J. (2003).
Crystal structure of the retinoblastoma tumor suppressor protein bound to
E2F and the molecular basis of its regulation. Proc. Natl. Acad. Sci. USA
100, 2363–2368.
Yee, C., Krishnan-Hewlett, I., Baker, C.C., Schlegel, R., and Howley, P.M.
(1985). Presence and expression of human papillomavirus sequences in
human cervical carcinoma cell lines. Am. J. Pathol. 119, 361–366.
Yoakim, C., Ogilvie, W.W., Goudreau, N., Naud, J., Hache´, B., O’Meara, J.A.,
Cordingley, M.G., Archambault, J., and White, P.W. (2003). Discovery of the
first series of inhibitors of human papillomavirus type 11: inhibition of the
assembly of the E1-E2-Origin DNA complex. Bioorg. Med. Chem. Lett. 13,
2539–2541.Ltd All rights reserved
